Vaccine co-administration in adults: An effective way to improve vaccination coverage

Hum Vaccin Immunother. 2023 Dec 31;19(1):2195786. doi: 10.1080/21645515.2023.2195786. Epub 2023 Apr 11.

Abstract

The ongoing COVID-19 pandemic highlights that complications and mortality associated with infectious diseases increase with age. Various vaccines are recommended for adults, but coverage rates remain suboptimal. Although co-administration would improve vaccine uptake and timely immunization, this is not routine practice in adults. We review key data on co-administration of vaccines in children and adults to reassure healthcare providers about its safety and advantages. In European countries and the United States, combined tetanus, diphtheria, and acellular pertussis boosters as well as meningococcal and human papillomavirus vaccines are recommended for healthy adolescents and adults of certain ages. Vaccination against influenza (annually), pneumococcal disease, and herpes zoster is recommended for older adults and specific risk groups. While co-administration is well established in children, it is less common in adults. Travelers can also receive multiple co-administered vaccines. Pediatric and travel vaccine co-administration has a well-established positive benefit-risk profile and is an efficient and cost-saving strategy to improve coverage. Healthcare providers could more often recommend and practice vaccine co-administration; this would not risk patient safety and health, would improve protection against vaccine-preventable diseases, and would help comply with national vaccination calendars. Recommending bodies may consider revising vaccination schedules to reduce the number of visits.

Keywords: Healthcare provider; concomitant; immunization; primary care; simultaneous; vaccine uptake.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Aged
  • COVID-19*
  • Child
  • Diphtheria-Tetanus-acellular Pertussis Vaccines*
  • Humans
  • Pandemics
  • Tetanus Toxoid
  • United States
  • Vaccination
  • Vaccination Coverage

Substances

  • Tetanus Toxoid
  • Diphtheria-Tetanus-acellular Pertussis Vaccines

Grants and funding

GlaxoSmithKline Biologicals SA took responsibility for all costs associated with developing and publishing the present manuscript.